Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Artemether And Lumefantrine · Coartem

Small molecule · developed by Novartis

Approved FDA, Apr 2009
NVS Developer

What is Artemether And Lumefantrine?

Artemether and lumefantrine is a fixed-dose oral combination of two antimalarial agents, artemether and lumefantrine, in a 1:6 ratio. It is used to treat acute, uncomplicated Plasmodium falciparum malaria, including in patients with a body weight of 5 kg and above, and is studied in uncomplicated P. falciparum malaria.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Coartem
Drug type
Small molecule
Therapy area
Infectious disease
Developer
Novartis (NVS)
FDA status
Approved as Coartem (April 7, 2009), NDA022268 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Mar 26, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Uncomplicated Plasmodium Falciparum Malaria

More from Novartis

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Artemether And Lumefantrine

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.